Advocacy Actions
European Chamber Nanjing Chapter Participated in the Nanjing ESG Investment Forum
On December 29, 2022, Mr Shan Jianhua, vice chair of the European Chamber Nanjing Chapter attended the Nanjing ESG Investment Forum and shared his insights on the investment environment and carbon neutrality future of Nanjing. This event aimed to build platforms for representatives from business community, government, and finance sectors to exchange and dialogue on the investment and sustainability, to build Nanjing a world-class city for investment and green development.
Read moreComments to State Administration for Market Regulation (SAMR) on the Anti-unfair Competition Law (Revised draft for comments)
European Chamber submitted comments to State Adminstration for Market Regulation (SAMR) on the Anti-unfair Competition Law of the People's Republic of China (Revised Draft for Comment), on 21st December 2022.
Read moreComments to China National Intellectual Property Administration (CNIPA) on the Patent Examination Guidelines (Revised draft for comment)
On 15th December, European Chamber IPR Working Group submitted comments to China National Intellectual Property Administration (CNIPA) on the Patent Examination Guidelines (Revised draft for comments).
Read moreAFB and Carbon Market Joint WG Meeting with the Netherlands Embassy on the Progress and Prospects for Agricultural Decarbonisation
On 15th December, the European Chamber’s Agriculture, Food and Beverage (AFB) Working Group and the Carbon Market Sub-Working Group organized a joint meeting on the progress and prospects for decarbonisation in the agriculture sector, where the Agricultural Counselor of Netherlands Embassy presented an overview of the agricultural sector in the Netherlands, highlighting the Dutch agricultural markets, greenhouse gas emissions, and the country's innovative land management approaches to reducing emissions.
Read moreComments to the National Medical Products Administration (NMPA) on the Provisions on Supervision and Administration of the Subject Responsibility for the Implementation of Drug Quality by Drug Marketing Authorisation Holders (Draft for Comments)
On 9th December, European Chamber Pharmaceutical Working Group submitted comments to the National Medical Products Administration (NMPA) on the Provisions on Supervision and Administration of the Subject Responsibility for the Implementation of Drug Quality by Drug Marketing Authorisation Holders (Draft for Comments).
Read moreComments to the Supreme People's Court (SPC) on the Judicial Interpretation for Civil Anti-Monopoly Actions (Draft for comments)
On 9th December, European Chamber submitted comments to the Supreme People's Court (SPC) on SPC's Judicial Interpretation for Civil Anti-Monopoly Actions (Draft for comments).
Read moreBanking and Securities Working Group Meeting with EUD
On 7th Dec, 2022, leading representatives of Delegation of the European Union to China had a briefing to industry members of Banking and Securities working group, regarding the key points exchanged during the EU-China High Level Dialogue on 2nd Dec, 2022.
Read moreMeeting with Development Research Center of Shanghai Municipal People's Government
29th November, Cindy He, European Chamber Shanghai Chapter Government Affairs Director, and Connor Yin, Working Group Coordinator met with Development Research Center of Shanghai Municipal People's Government, to discuss how to promote Shanghai's economic influence globally.
Read moreEuropean Chamber representatives meet with European Council President Charles Michel
On 25th November, a delegation of European Chamber representatives led by President Joerg Wuttke met with European Council President Charles Michel ahead of his visit to China.
Read moreEuropean Chamber Co-organises EU-China Biopharmaceutical Innovation and Development Roundtable
On 24th November 2022, the EU-China Biopharmaceutical Innovation and Development Roundtable took place using a hybrid format connecting Beijing and Brussels.
The roundtable, co-organised by the European Chamber and the China Society for Drug Regulation (CSDR), with the support from the European Federation of Pharmaceutical Industries and Associations (EFPIA), enabled an open dialogue on pro-innovation regulatory policies between representatives from the European pharmaceutical industry and the National Medical Products Administration (NMPA).